NASDAQ$RLAY
Relay Therapeutics Inc. · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Reported fourth quarter and full year 2023 financial results and corporate highlights.
Relay Therapeutics reported its Q4 and full year 2023 financial results, highlighting progress across its portfolio, including advancing multiple clinical programs and investing in its Dynamo platform. The company's cash, cash equivalents, and investments totaled approximately $750 million at the end of Q4 2023, expected to fund operations into the second half of 2026.
- Completed enrollment in initial RLY-2608 600mg + fulvestrant dose expansion cohort.
- Initiated additional dose expansion cohorts with RLY-2608 400mg & 600mg.
- Initiated RLY-2608 + fulvestrant + ribociclib triplet combination in PI3Kα-mutated HR+/HER2- metastatic breast cancer.
- Approximately $750 million in cash, cash equivalents and investments at end of Q4 2023, expected to fund operations into second half of 2026.
Headline financials
Revenue & EPS history
Relay Therapeutics · Revenue · Quarterly
-$1K
Revenue by segment
Relay Therapeutics · $25.2M total across 1 segment · Q3 2023
- License and Other Revenue$25.2M—100.0%
Forward guidance
Relay Therapeutics anticipates several milestones in 2024, including RLY-2608 data updates, initial safety data for RLY-2608 in combination with fulvestrant and ribociclib, a lirafugratinib tumor agnostic data and regulatory update, and the disclosure of new pre-clinical programs.
Tailwinds
- RLY-2608 + fulvestrant data update in the second half of 2024
- RLY-2608 + fulvestrant + ribociclib initial safety data in the second half of 2024
- Lirafugratinib: tumor agnostic data and regulatory update in the second half of 2024
- Pre-clinical: disclose new program(s) in 2024
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2023
+0.2%
Avg return
Earnings day
-0.4%
Avg return
5 days after
-0.5%
Avg return
30 days after
57%
13 / 23 earnings
Positive
+11.7%
Q4 2025
Best reaction
-19.5%
Q1 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -0.7% | -2.5% | +11.1% | |
| Q4 2025 | +11.7% | +10.8% | +4.8% | |
| Q3 2025 | -7.4% | -5.5% | +17.6% | |
| Q1 2025 | -4.8% | -9.6% | -2.4% | |
| Q4 2024 | -13.3% | -14.9% | -27.5% | |
| Q3 2024 | +3.2% | +3.5% | -22.5% | |
| Q2 2024 | -6.8% | -5.6% | -8.6% | |
| Q1 2024 | +5.7% | +1.2% | -3.8% | |
| Q4 2023 | -4.6% | -1.8% | -25.7% | |
| Q3 2023 | +10.1% | +19.3% | +27.4% | |
| Q2 2023 | +7.8% | +3.5% | -3.2% | |
| Q1 2023 | +0.5% | -5.3% | +2.3% | |
| Q4 2022 | -3.6% | -8.8% | -13.5% | |
| Q3 2022 | -4.3% | -6.8% | -12.4% | |
| Q2 2022 | +3.8% | -1.6% | +31.7% | |
| Q1 2022 | -19.5% | -33.5% | -31.6% | |
| Q4 2021 | +11.5% | +17.4% | +40.1% | |
| Q3 2021 | +1.7% | +0.6% | -19.6% | |
| Q2 2021 | +1.0% | +0.2% | -1.7% | |
| Q1 2021 | +5.7% | +8.5% | +23.9% | |
| Q4 2020 | -2.3% | +2.0% | -13.5% | |
| Q3 2020 | +0.5% | +13.5% | +5.7% | |
| Q2 2020 | +8.0% | +5.3% | +8.5% | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro